UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge

Aug 5 (Reuters) - Bristol-Myers Squibb Co said its
blockbuster Opdivo immunotherapy failed to slow progression of
symptoms in previously untreated patients with advanced lung
cancer, a major setback...